TempraMed Signs Letter of Intent with CPO Cyprus for Exclusive Distribution of VIVI Products in Cyprus
Cyprus would become an additional European market for the two products if the parties complete a definitive agreement.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
TempraMed (TMPTF) signed a non-binding letter of intent with CPO Cyprus for proposed exclusive distribution of VIVI Cap and VIVI Epi in Cyprus.
The letter is dated July 31, 2026. Exclusivity would depend on a definitive agreement and minimum purchase obligations. To retain it, CPO Cyprus would have to increase combined annual purchases of the two products by at least 20% year over year. Transfer prices and the first-year minimum combined unit commitment are to be established in the definitive agreement. The parties have 90 days from July 31 to conclude that agreement, unless they mutually extend the period.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.Proposed exclusive distribution would bring VIVI Cap and VIVI Epi to Cyprus through CPO Cyprus.
- Minor point. Forward-looking: it has not happened yet and may not happen.At least 20% annual growth in combined purchases would be required to maintain the proposed exclusivity.
Negative
- Moderate pointNon-binding letter of intent leaves the distribution arrangement subject to a definitive agreement.
- Minor point90 days from July 31, 2026 are provided to conclude the agreement unless both parties extend the period.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Distribution partnership with one of Cyprus's most established healthcare and consumer-products distributors
Highlights:
- LOI with CPO Cyprus includes exclusive distribution of VIVI Cap™ and VIVI Epi™ throughout Cyprus, subject to a definitive agreement.
- Proposed exclusivity is conditional on minimum annual purchase obligations, with combined purchases required to increase by at least
20% year over year to maintain exclusivity. - Transfer pricing and the first-year minimum combined unit commitment will be negotiated and established in the definitive distribution agreement.
- CPO Cyprus brings nearly a century of local market experience and established distribution capabilities spanning pharmaceutical products, medical instruments and hospital equipment.
Toronto, Ontario--(Newsfile Corp. - September 29, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (OTCQB: TMPTF) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that it has signed a non-binding letter of intent (the "LOI") dated July 31, 2026 with Cyprus Pharmaceutical Organization Ltd. ("CPO Cyprus") regarding the proposed exclusive distribution of VIVI Cap™ and VIVI Epi™ in Cyprus.
Under the LOI, TempraMed proposes to appoint CPO Cyprus as the exclusive distributor of VIVI Cap and VIVI Epi in Cyprus, subject to the execution of a definitive distribution agreement and CPO Cyprus's compliance with minimum purchase obligations. The specific transfer prices and first-year minimum combined unit commitment have not yet been finalized and are to be established in the definitive agreement.
To maintain the proposed exclusivity, CPO Cyprus would be required to increase its total annual combined purchases of VIVI Cap and VIVI Epi by no less than
CPO Cyprus was founded in Nicosia in 1928 and, according to CPO Group, has grown to rank among the 20 largest trading firms in Cyprus. The company is an importer, distributor and exclusive agent across the health, beauty, personal-care and food sectors, with products ranging from pharmaceuticals to specialized medical instruments and hospital equipment.
TempraMed believes CPO Cyprus's healthcare-market experience, established local relationships and distribution capabilities make it a strong prospective partner for the Company's entry into Cyprus.
The proposed relationship supports TempraMed's strategy of expanding through experienced local partners that can navigate country-specific healthcare channels and build sustained product adoption. If a definitive agreement is completed, Cyprus would become an additional European market for two of TempraMed's commercial medication-protection products.
"CPO Cyprus is exactly the kind of established, market-facing partner we want as we expand TempraMed's global commercial footprint," said Ron Nagar, Founder and CEO of TempraMed. "With roots in Cyprus dating back nearly a century and broad experience across pharmaceutical and medical-product distribution, CPO Cyprus offers a strong prospective platform for introducing VIVI Cap and VIVI Epi nationwide. The proposed annual purchase-growth requirement reflects our intention to build this relationship for scale. We are focused on converting this LOI into a definitive agreement and, subject to completing that agreement and satisfying all applicable requirements, making Cyprus another meaningful market for TempraMed. This planned expansion further demonstrates the international relevance of our passive, battery-free technology for people who rely on temperature-sensitive medications."
About CPO Cyprus
Founded in Nicosia in 1928 as C.A. Papaellinas & Co. and renamed Cyprus Pharmaceutical Organization in 1952, CPO Cyprus is the largest subsidiary of CPO Group and has grown to be among the 20 largest trading firms in Cyprus. The company operates as an importer, distributor and exclusive agent in the health, beauty, personal-care and food sectors. Its portfolio ranges from mass-market and pharmaceutical products to specialized medical instruments and hospital equipment. For more information, visit www.cpogroup.cy.
About TempraMed Technologies Ltd.
TempraMed Technologies Ltd. is a global medical-device company with a portfolio of innovative, temperature-controlled medication-storage solutions. Founded with the mission to safeguard the effectiveness of life-saving medications, TempraMed develops patented, FDA-registered thermal-insulation devices that operate continuously without batteries or external power. Its commercial product portfolio includes VIVI Cap™, VIVI Cap Smart™, VIVI Epi™ and VIVI Med™. TempraMed enables patients and healthcare providers to confidently manage temperature-sensitive medications anywhere, anytime.
Investors interested in learning more about TempraMed are encouraged to contact the Company at:
ir@tempramed.com
www.tempramed.com
Contact:
Julia Becker
Vice President, Capital Markets
T: +1 (604) 785-0850
E: julia@tempramed.com
Media:
Brenda Zeitlin
Vice President, Marketing
E: brenda@tempramed.com
Cautionary Statements
THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE, NOR HAS OR DOES THE CSE'S REGULATION SERVICES PROVIDER.
This press release contains "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian securities legislation. Forward-looking statements may be identified by words such as "anticipate," "believe," "expect," "intend," "may," "plan," "potential," "should," "strategy," "will" and similar expressions, or statements concerning events or conditions that may occur in the future.
Forward-looking statements in this press release include, without limitation, the negotiation, execution and timing of a definitive distribution agreement with CPO Cyprus; the terms of any such agreement, including transfer pricing, minimum purchase obligations and the conditions of exclusivity; the appointment of CPO Cyprus as exclusive distributor of VIVI Cap and VIVI Epi in Cyprus; the anticipated benefits of the proposed relationship; the Company's strategy of expanding through local distribution partners and its ability to enter Cyprus and other European markets; the addition or renewal of distribution agreements in other jurisdictions; regulatory clearance and import requirements for the Company's products in Cyprus; consumer adoption of the Company's products; and the Company's ability to expand its commercial presence in Cyprus.
Forward-looking statements are based on the opinions, expectations and assumptions of management as of the date of this press release, including assumptions that the parties will successfully negotiate and execute a definitive distribution agreement on terms consistent with the LOI; that CPO Cyprus will satisfy the conditions to exclusivity; that required regulatory approvals and import clearances will be obtained; and that demand for temperature-protection solutions for injectable medications will continue.
Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied, including: that the LOI is non-binding and there is no assurance that a definitive agreement will be entered into, or, if entered into, that it will be on the terms contemplated by the LOI or within the anticipated timeframe; the risk that the parties may be unable to agree on transfer pricing, minimum purchase commitments or other material terms; the risk that CPO Cyprus may not meet minimum purchase obligations or the
Except as required by applicable securities laws, the Company undertakes no obligation to update or revise publicly any forward-looking statements.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/316370
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What must CPO Cyprus do to keep exclusive distribution rights for TempraMed’s VIVI products?
CPO Cyprus would have to increase its combined annual purchases of VIVI Cap and VIVI Epi by at least 20% year over year to maintain the proposed exclusivity. The arrangement remains subject to a definitive distribution agreement.